Phase III Studies Confirm Statistically Significant Clinical Benefit of Continuous REVLIMID Treatment (CELG)

Celgene International Sarl CELG today announced data from multiple phase III studies evaluating the benefit/risk profile of REVLIMID were presented during the International Myeloma Workshop in Paris, France. The updated results were from four phase III studies of REVLIMID (lenalidomide), either as continuous therapy following high-dose melphalan and autologous stem cell therapy, as continuous therapy following induction with melphalan, prednisone and lenalidomide in patients with newly diagnosed multiple myeloma, or as therapy with lenalidomide plus dexamethasone as induction followed by continuous lenalidomide therapy in patients with smoldering multiple myeloma. Also presented was a retrospective safety analysis of 11 Celgene-sponsored trials evaluating lenalidomide plus dexamethasone in relapsed/refractory multiple myeloma patients.